Study of HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab. Phase 2
Abstract
The primary purpose of this grant is to determine the relapse free survival benefit with locally advanced and stage IV HER2 positive breast cancer patients vaccinated with a HER2 ICD peptide-based vaccine while receiving maintenance trastuzumab. The scope of work includes a Phase II single arm study of a HER2 ICD peptide-based vaccine given concurrently with trastuzumab. Fourteen patients have been enrolled during the last reporting period. All adverse events reported for these fourteen subjects are of low grade. Patients have developed significant T cell immune responses to the vaccine as we as epitope spreading indicating a Type I immune response is being elicited.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2009
- Accession Number
- ADA505213
Entities
People
- Mary L. Disis
Organizations
- Seattle University